May 20 – 22, 2020
This program will offer key lessons involving health reform under the new federal administration. The nation’s leading health policy experts will explain essential lessons from current reform efforts, anticipate the next round of policy innovations, and offer strategies to thrive in the evolving health care marketplace.
U.S. medical care has experienced huge and unsustainable spending increases—especially in drug prices—for decades. Under the Affordable Care Act, the Obama administration accelerated the value-based care movement to address key spending categories such as hospital and physician care. Value-based purchasing seeks to reduce spending by improving quality and efficiency to address unnecessary costs. Most stakeholders … Continue reading “Putting the Drug Debate into Context: the State of Pharmaceutical Cost Reform in the U.S.”
Prescription drug prices in the U.S. have been rising at an alarming rate, contributing to the nation’s high health care costs. This concerns policy makers at the state and federal levels, prompting exploration of new options to get a better handle on costs while maintaining Americans’ access to pharmacological innovations. Putting Drug Prices into Context … Continue reading “The Need to Treat the Ailing U.S. Pharmaceutical Pricing System”
Uncertainty and rapid change continue to impact the U.S. health care sector, with questions persisting about the fate of the Affordable Care Act (ACA) and U.S. health reform in the Trump era. This is a period of shifting priorities. Consider the new partnership involving Amazon, Berkshire Hathaway, and JPMorgan Chase to launch their own health … Continue reading “How Health Care Executives Can Lead for Success in the Post-ACA Era”
Today the ACA is still alive. Donald Trump’s campaign boast that he would sign a bill repealing the Affordable Care Act (ACA/Obamacare) on his inauguration day is long gone and forgotten. House Speaker Paul Ryan and Senate Majority Leader Mitch McConnell’s gamble that by April 28th the ACA would be effectively decimated using the expedited … Continue reading “The ACA Is Still Alive and Still in Danger”
These are uncertain times in American health care. The Republican Congress and President Trump have vowed to repeal and replace the Patient Protection and Affordable Care Act (ACA), commonly called Obamacare. They recently unveiled the American Health Care Act, the replacement plan, which has met with substantial resistance from all parts of the political spectrum. … Continue reading “Exploring the Next Phase of Health Care Reform: How Health Care Leaders Can Position Their Organizations for Success”
In August 2014, the World Health Organization (WHO) declared the Ebola outbreak then raging in West Africa a “public health emergency of international concern,” a formal designation by the WHO’s Emergency Committee that reflects the fact that the disease was spreading internationally and posed a risk to other countries yet unaffected. By the time the … Continue reading “Vaccinating Against an Epidemic: The Story of an Ebola Vaccine”
The passage of the Affordable Care Act has been profitable for pharmaceutical companies in the U.S., with more Americans now having access to prescription drugs. But as this article explores, there are many complexities inherent in the drug industry that need to be addressed moving forward.
Many factors could be blamed for the spread of tuberculosis in a rural Alabama town earlier this year, including its residents’ fears of being stigmatized in a small town, poverty line, and the legacy of the Tuskegee experiments.
On Mother’s Day, 2003, 5-year-old Matthew Siravo, who had epilepsy, died at Boston Children’s Hospital, two days after suffering a seizure that lasted an hour and a half. Siravo’s story made headlines in the local news, and in September of that year, the Massachusetts Department of Public Health issued what The Boston Globe called “a … Continue reading “Equipping Physicians To Manage The Rapidly Evolving World of Health Care”
